StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
MIJ.SI$0.16+2.50%
Fair $0.16+0.0%

MIJ.SI

Alliance Healthcare Group Limited

Healthcare / Medical Care FacilitiesSES

$0.16

+0.00 (+2.50%)

Fairly Valued+0.0%Fair Value $0.16Fund rank 30/100 · Data gapFallback financials|
SA 68/B
F-Score: 8/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 26% · confianza 25%

FCF escenarios

weak_data · normalized FCF $1.1M · quality 46.0/100

Data gap 30/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 42/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

68/100

B

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · MIJ.SILocal privado en este navegador · Alliance Healthcare Group Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$34M

P/E

16.4x

↓

EV/EBITDA

5.2x

↓

ROE

6.3%

↑

Gross Margin

74.2%

↑

Debt/Equity

0.73

↑
52-Week Range$0
$0$0

TradingView lightweight chart

MIJ.SI price, volumen y niveles de valoración

Último $0.164Periodo -20.0%
Fair value: $0.164

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+12.1%

FCF CAGR

-24.0%

FCF margin

5.3%

FCF / Net income

2.70x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $77.1M · net income $1.5M · FCF $4.1M

2022-FY → 2025-FY

Gross margin

74.2%+2.7% pts

Operating margin

11.1%-3.0% pts

Net margin

2.0%-3.7% pts

FCF margin

5.3%-11.8% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$77.1M$77.1M$68.0M$58.0M$54.8M
Net Income$1.5M$1.5M$719752.00$2.1M$3.1M
EBITDA$6.7M$6.7M$4.9M$5.4M$8.0M
EPS0.010.010.000.010.01
Gross Margin74.2%74.2%70.9%68.5%71.4%
Operating Margin11.1%11.1%8.5%11.4%14.1%
Net Margin2.0%2.0%1.1%3.6%5.7%
Balance Sheet
Debt/Equity0.730.730.920.600.39
Current Ratio1.171.17———
Cash Flow
Free Cash Flow$4.1M$4.1M$1.1M$173567.00$9.4M
Returns
ROE6.3%6.3%3.2%9.2%14.1%
Valuation
P/E16.4016.4038.5717.6511.40
EV/EBITDA5.225.226.125.822.93
P/B1.391.391.221.621.60
Growth & Yield
Revenue Growth13.4%13.4%17.2%5.9%—
EPS Growth111.4%111.4%-65.7%-32.0%—
Dividend Yield0.6%0.6%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

25.3%

muy exigente

EPS terminal req.

$0.01

Spread vs growth

86.1%

5Y implied EPS CAGR

18.9%

exigente

EPS terminal req.

$0.02

Spread vs growth

92.5%

10Y implied EPS CAGR

14.4%

razonable

EPS terminal req.

$0.03

Spread vs growth

97.0%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +63.0%

Total return

+63.0%

Start / end P/E

28.9x → 22.2x

EPS bridge

0.00 → 0.01

Residual

-25.9%

EPS growth+111.4%
Multiple rerating-23.2%
Dividend+0.6%
Residual / FX / buybacks / cross-term-25.9%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.